At a glance
A short peptide explored in experimental endocrine regulation.
This profile separates the compound’s scientific background from specification-specific preparation and source schedules. Begin with the research findings and limitations, then select the formulation you want to examine.
How it works
Potential benefits & side effects
Interpret each outcome in the context of the study population, formulation and evidence type. Research findings do not establish a personal treatment outcome.
Potential benefits & research findings
The source describes preclinical hormonal findings. They do not establish a human testosterone or thyroid treatment.[3][4][2]
Read the original publications to see the measured endpoints, comparator, duration and uncertainty. Mechanistic plausibility and a favorable experimental result are different from demonstrated clinical benefit.
Side effects & evidence limitations
Interpret the reported adverse effects together with the study population, route and observation period. Small or short studies can miss uncommon and delayed harms. Evidence from a related compound does not establish the safety of Testagen.
Source-reported adverse effects and cautions
Sources are available for independent reading. Individual claims and research schedules have not yet undergone an independent clinical review by Pep Science.
- Editorial responsibility
- Pep Science editorial desk
- Last independent review
- Not yet recorded
SPECIFICATIONS & SOURCE SCHEDULES
Explore a vial size
Select the exact formulation. Vial content, target dose and prepared concentration are different measurements.
Showing 20 mg · 1 source tables
Standard / Gradual Approach (3 mL = ~6.67 mg/mL)
| Week | Daily Dose (mcg) | Units (per injection) (mL) |
|---|---|---|
| Weeks 1–2 | 100 mcg (0.1 mg) | 1.5 units (0.015 mL) |
| Weeks 3–4 | 150 mcg (0.15 mg) | 2.25 units (0.0225 mL) |
| Weeks 5–8 | 200 mcg (0.2 mg) | 3 units (0.03 mL) |
| Weeks 9–12 (optional) | 250–300 mcg (0.25–0.3 mg) | 3.75–4.5 units (0.0375–0.045 mL) |
Frequency: Inject once daily subcutaneously, consistent with preclinical study protocols[3][4]. For ≤10‑unit (≤0.10 mL) administrations, consider 30‑ or 50‑unit insulin syringes for improved readability.
Additional schedule context & duration
Concise summary of the once‑daily regimen.
- Goal: Support endocrine function research, particularly pituitary–gonadal axis modulation[1][2].
- Schedule: Daily subcutaneous injections for 8–12 weeks (extend to 16 weeks if desired).
- Dose Range: 100–300 mcg daily with gradual titration.
- Reconstitution: 3.0 mL per 20 mg vial (~6.67 mg/mL) for accurate unit measurements.
- Storage: Lyophilized frozen; reconstituted refrigerated; avoid repeated freeze–thaw.
Suggested daily titration approach.
- Start: 100 mcg daily; increase by ~50 mcg every 2 weeks as tolerated.
- Target: 200–300 mcg daily by Weeks 5–12.
- Frequency: Once per day (subcutaneous).
- Cycle Length: 8–12 weeks; optional extension to 16 weeks.
- Timing: Any consistent time; rotate injection sites.
Preparation
Reconstitution Steps
- Draw 3.0 mL bacteriostatic water with a sterile syringe.
- Inject slowly down the vial wall; avoid foaming.
- Gently swirl/roll until dissolved (do not shake)[5].
- Label and refrigerate at 2–8 °C (35.6–46.4 °F), protected from light.
Storage Instructions
Proper storage preserves peptide quality[5][6].
- Lyophilized: Store at −20 °C (−4 °F) in dry, dark conditions; minimize moisture exposure.
- Reconstituted: Refrigerate at 2–8 °C (35.6–46.4 °F); prepare aliquots if needed and avoid freeze–thaw.
- Allow vials to reach room temperature before opening to reduce condensation uptake.
Injection Technique
General subcutaneous guidance from clinical best‑practice resources[9].
- Clean the vial stopper and skin with alcohol; allow to dry[7].
- Pinch a skinfold; insert the needle at 45–90° into subcutaneous tissue[7][8].
- Do not aspirate for subcutaneous injections; inject slowly and steadily[7].
- Rotate sites systematically (abdomen avoiding 2″ around navel, thighs, upper arms) to avoid tissue damage[8].
- Use a fine gauge needle (23–25 G, ½–⅝″) for comfort[7].
Materials & quantity planning
Source materials checklist · 20 mg
Plan based on an 8–16 week daily protocol with gradual titration.
-
Peptide Vials (Testagen, 20 mg each):
- 8 weeks (~14 mg used) ≈ 1 vial
- 12 weeks (~25 mg used) ≈ 2 vials
- 16 weeks (~36 mg used) ≈ 2 vials
-
Insulin Syringes (30‑ or 50‑unit recommended for low‑volume accuracy):
- Per week: 7 syringes (1/day)
- 8 weeks: 56 syringes
- 12 weeks: 84 syringes
- 16 weeks: 112 syringes
-
Bacteriostatic Water (10 mL bottles): Use ~3.0 mL per vial for reconstitution.
- 8 weeks (1 vial): 3 mL → 1 × 10 mL bottle
- 12 weeks (2 vials): 6 mL → 1 × 10 mL bottle
- 16 weeks (2 vials): 6 mL → 1 × 10 mL bottle
-
Alcohol Swabs: One for the vial stopper + one for the injection site each day.
- Per week: 14 swabs (2/day)
- 8 weeks: 112 swabs → recommend 2 × 100‑count boxes
- 12 weeks: 168 swabs → recommend 2 × 100‑count boxes
- 16 weeks: 224 swabs → recommend 3 × 100‑count boxes
Calculate a phased quantity
Enter each finite phase from the schedule you are studying. Open-ended phases need an explicit duration. Calculation uses 20 mg per vial and 3 mL per vial.
Complete each phase to calculate totals.
Quantity estimates exclude preparation losses and expiry. Follow the formulation’s handling and disposal requirements.
FOLLOW THE EVIDENCE
References & further reading
Original publications and source documents cited across this product’s variants. A listed source is not an independent endorsement of a dosing schedule.
- 03
Research publication
PubMed — Effects of hypophyseal Lys‑Glu‑Asp‑Gly peptide on immunity, hemostasis, and thyroid function in hypophysectomized chickens (opens in a new tab)pubmed.ncbi.nlm.nih.gov
Back to overview ↑ - 04
Research publication
PubMed — Effects of Lys‑Glu‑Asp‑Gly peptide on hormonal activity and thyroid morphology in hypophysectomized mature and old birds (opens in a new tab)pubmed.ncbi.nlm.nih.gov
Back to overview ↑ - 05
- 07
Public health resource
CDC — Vaccine Administration: Subcutaneous Injection Technique (angle, site, no aspiration) (opens in a new tab)www.cdc.gov
Back to overview ↑ - 08
Public health resource
MedlinePlus — Subcutaneous (SQ) Injections: Patient Instructions (site rotation and technique) (opens in a new tab)medlineplus.gov
Back to overview ↑ - 09
Public health resource
PMC — Subcutaneous Drug Delivery: Pharmacologic Considerations and Clinical Practice (opens in a new tab)www.ncbi.nlm.nih.gov
Back to overview ↑ - 10
Public health resource
PMC — Subcutaneous Injection Route: Pharmacokinetics and Clinical Applications Review (opens in a new tab)www.ncbi.nlm.nih.gov
Back to overview ↑ - 11
Public health resource
NCBI Bookshelf — Best Practices for Injection (asepsis, preparation, and administration) (opens in a new tab)www.ncbi.nlm.nih.gov
Back to overview ↑
Continue exploring
Related topics are not interchangeable compounds or formulations.